Track Vivani Medical Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Vivani Medical Inc. Common Stock VANI · Stock Open Vivani Medical Inc. Common Stock in new tab

1.12 USD
EPS
-0.36
P/B
5.61
ROE
-220.41
Beta
3.30
Target Price
3.83 USD
Loading chart...
Key Metrics
Earnings dateNov. 12, 2026
EPS-0.36
Book Value0.21
Price to Book5.61
Debt/Equity94.14
% Insiders55.391%
Estimates
Forward P/E-3.40
Forward EPS-0.35
Target Mean Price3.83

DCF valuation

Model fair value for Vivani Medical Inc. Common Stock (VANI)
Result
Sign in to run the valuation for VANI.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus None · mean target 3.83 USD (low 3.50, high 4.00) · as of 13 Oct 2026
Low 3.50
Mean 3.83
High 4.00
Price 1.12
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Vivani Medical Inc. Common Stock Logo Vivani Medical Inc. Common Stock Analysis (VANI)

United States Health Care Official Website Stock

Is Vivani Medical Inc. Common Stock a good investment? Vivani Medical Inc. Common Stock (VANI) is currently trading at 1.12 USD. Market analysts have a consensus price target of 3.83 USD. This suggests a potential upside from current levels.

Earnings Schedule: Vivani Medical Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.35.

Investor FAQ

Does Vivani Medical Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Vivani Medical Inc. Common Stock?

Vivani Medical Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.36.

Company Profile

Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.

Exchange Ticker
NMS (United States) VANI
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Jan. 6, 2020 1:8
Aug. 19, 2022 1:3
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion